| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pathology and Laboratory Medicine (Z.Z., R.C., M.G., Y.E.N.), University of Cincinnati, Cincinnati, Ohio 45267; and Division of Pathology (M.N.N.), Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio 45229
Address all correspondence and requests for reprints to: Dr. Yuri Nikiforov, Department of Pathology, University of Cincinnati, 231 Albert Sabin Way, P.O. Box 670529, Cincinnati, Ohio 45267-0529. E-mail: Yuri.Nikiforov{at}uc.edu.
Context: RET/PTC rearrangements have been reported in papillary thyroid carcinomas with variable frequency in studies that used different detection methods.
Objective: Our objective was to determine the role of different detection methods and tumor genetic heterogeneity on RET/PTC detection.
Design: Sixty-five papillary carcinomas were analyzed for RET/PTC1 and RET/PTC3 using five detection methods: standard-sensitivity RT-PCR, high-sensitivity RT-PCR, real-time LightCycler RT-PCR, Southern blot analysis, and fluorescence in situ hybridization.
Results: RET/PTC rearrangements were detected by standard-sensitivity RT-PCR in 14 tumors. High-sensitivity RT-PCR detected RET/PTC in all of these and in 12 additional cases, where the levels of expression corresponded to one to five positive cells. Real-time LightCycler RT-PCR detected RET/PTC in 12 and Southern blot analysis in 11 tumors. By fluorescence in situ hybridization, 14 tumors were positive, including nine cases with 5086% positive cells and five cases with 1735% positive cells. Overall, nine (14%) tumors harbored clonal rearrangements, which were present in the majority of tumor cells and detected by all five methods. Five (8%) cases had subclonal rearrangements present in a smaller portion of tumor cells and detected by most methods. Twelve (18%) tumors had nonclonal RET/PTC that were detected only by high-sensitivity RT-PCR. No other mutations were found in tumors harboring clonal RET/PTC, whereas 60% of tumors with subclonal and 42% of tumors with nonclonal RET/PTC harbored additional mutations.
Conclusions: Our data suggest that broad variability in the reported prevalence of RET/PTC rearrangement is at least in part a result of the use of different detection methods and tumor genetic heterogeneity.
This article has been cited by other articles:
![]() |
J. C. Ricarte-Filho, M. Ryder, D. A. Chitale, M. Rivera, A. Heguy, M. Ladanyi, M. Janakiraman, D. Solit, J. A. Knauf, R. M. Tuttle, et al. Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA, and AKT1 Cancer Res., June 1, 2009; 69(11): 4885 - 4893. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. C. Henderson, T. D. Shellenberger, M. D. Williams, A. K. El-Naggar, M. J. Fredrick, K. M. Cieply, and G. L. Clayman High Rate of BRAF and RET/PTC Dual Mutations Associated with Recurrent Papillary Thyroid Carcinoma Clin. Cancer Res., January 15, 2009; 15(2): 485 - 491. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Eszlinger, K. Krohn, S. Hauptmann, H. Dralle, T. J. Giordano, and R. Paschke Perspectives for Improved and More Accurate Classification of Thyroid Epithelial Tumors J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3286 - 3294. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Romei, R. Ciampi, P. Faviana, L. Agate, E. Molinaro, V. Bottici, F. Basolo, P. Miccoli, F. Pacini, A. Pinchera, et al. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer Endocr. Relat. Cancer, June 1, 2008; 15(2): 511 - 520. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. V. Frau, M. L. Lai, P. Caria, T. Dettori, P. Coni, G. Faa, L. Morandi, G. Tallini, and R. Vanni Trisomy 17 as a Marker for a Subset of Noninvasive Thyroid Nodules with Focal Features of Papillary Carcinoma: Cytogenetic and Molecular Analysis of 62 Cases and Correlation with Histological Findings J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 177 - 181. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Riesco-Eizaguirre and P. Santisteban New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy Endocr. Relat. Cancer, December 1, 2007; 14(4): 957 - 977. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ciampi and Y. E. Nikiforov RET/PTC Rearrangements and BRAF Mutations in Thyroid Tumorigenesis Endocrinology, March 1, 2007; 148(3): 936 - 941. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Santoro, R. M. Melillo, and A. Fusco RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur. J. Endocrinol., November 1, 2006; 155(5): 645 - 653. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |